[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cbt\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cbt":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,43,68,89,119,148,172,209,239],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100366076","pain-and-weight-treatment-development-and-trial-of-paw-100366076",false,"NCT04046562","Pain and Weight Treatment: Development and Trial of PAW","PAW","Inclusion Criteria:\n\n* Males and females between 12 and 18 years of age\n* Ability to speak, write and read English\n* A parent or guardian who speaks, writes and reads English\n* Signed consent and assent from the child and parent\n* Enrollment in a weight management program\n* Score greater than 3 on the Pain Burden Inventory at screening (in order to recruit adolescents who experience more than just general aches and pains).\n* Youth reporting musculoskeletal pain\n\nExclusion Criteria:\n\n* Parent or guardian unable to participate\n* Patients on weight reducing medications\n* Severe psychiatric illness (i.e., suicidal or hospitalization within past 6 months)\n* Medical conditions such as Type 1 diabetes","ALL","12 Years","18 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"NA","Pediatric weight management efficacy is impacted by failure to complete treatment protocols and, for those that do complete treatment, a return to unhealthy behaviors. This project tests whether treating pain, a common comorbid condition to pediatric obesity, will enhance treatment. This study will generate results that can be translated into immediate improvements in care for families seeking treatment for pediatric obesity.",[27,28,29],"Obesity, Adolescent","Pain, Chronic","CBT","RECRUITING","2026-06-29",{"date":33,"type":34},"2026-07-01","ACTUAL",{"date":36,"type":34},"2019-08-14",{"date":38,"type":21},"2027-06",{"name":40,"class":41},"Connecticut Children's Medical Center","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":42},"100607850","adaptation-of-the-eccclore-program-for-patients-with-addictive-and-traumatic-problems-100607850","NCT07193914","Adaptation of the ECCCLORE Program for Patients With Addictive and Traumatic Problems","Adaptation of the ECCCLORE Program for Patients With Addictive and Traumatic Problems: Feasibility and Acceptability","PEAT","Inclusion Criteria:\n\n* Patients with one or more addictions\n* ASSIST questionnaire score greater than or equal to 11 for alcohol consumption and greater than or equal to 4 for other substances.\n* Diagnosis of PTSD and\u002For CPTSD assessed using the ITQ scale.\n* Ability to understand, write, and read French\n* The patient must have given their free and informed consent\n* The patient must be a member or beneficiary of a health insurance plan\n\nExclusion Criteria:\n\n* The subject is participating in an interventional study involving a drug or medical device or a Category 1 study within 3 months prior to inclusion\n* The patient is under safeguard of justice or state guardianship\n* Patients with a psychotic disorder\n* Patients with severe cognitive impairment (MoCA \\\u003C 10)\n* Patients experiencing a manic or hypomanic episode\n* Patients experiencing a major depressive episode\n* Patients participating in an interventional study involving a drug or medical device or a Category 1 RIPH within 3 months prior to inclusion\n* Pregnant, parturient, or breastfeeding woman",{"count":52,"type":21},30,[24],"Complex posttraumatic stress disorder (cPTSD) is characterized by chronic and pervasive disruptions in emotion regulation, identity, and relationships following prolonged or multiple exposures to trauma. It is frequently found in patients with addiction. Individuals with cPTSD have more severe addiction. In addition, the co-occurrence of these two disorders is often associated with certain transdiagnostic processes such as impulsivity. Indeed, PTSD is linked to a higher impulsivity score, which in turn promotes increased substance use. A second process also associated with trauma and addiction is hostile attribution bias.\n\nThus, the trauma-addiction comorbidity generates multiple behavioral consequences (aggression, increased substance use, etc.) that impact patients' quality of life and represent an important treatment target. Many authors and clinicians have worked on creating treatment programs targeting both disorders, although group format treatment lacks empirical support. Indeed, even though the Seeking Safety program has been shown to be effective in reducing PTSD symptoms and substance use, there is currently no evidence to suggest its superiority.\n\nThe ECCCLORE program is a new 6-month cognitive behavioral therapy protocol initially designed for patients with borderline personality disorder, in whom addictive and traumatic issues are common. It is shorter than the standard dialectical behavioral therapy (DBT) program, which focuses on emotional dysregulation, impulsivity, and the traumatic dimension and lasts at least 1 year. It also integrates techniques from other approaches such as Acceptance and Commitment Therapy (ACT), which promotes the acceptance of internal experiences and engagement in actions consistent with values. It notably contains tools for developing emotional, distress tolerance, and interpersonal skills that could adapt to the difficulties generated by trauma and addiction. The objective of this research is to test the feasibility and acceptability of a 12-week ECCCLORE program adapted for patients with addictive and traumatic problems. The study investigators hypothesize that the implementation of this program will demonstrate satisfactory feasibility and acceptability.",[56,57,58,29],"PTSD","Addiction","Substance Use Disorders","2026-01-27",{"date":61,"type":34},"2026-01-28",{"date":63,"type":34},"2025-10-31",{"date":65,"type":21},"2027-03",{"name":67,"class":41},"Centre Hospitalier Universitaire de Nīmes",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":42},"100497572","blended-treatment-fr-ptsd-a-new-format-of-computer-assisted-trauma-focused-cognitive-behavioral-therapy-100497572","NCT05758987","Blended Treatment för PTSD: A New Format of Computer-Assisted Trauma-Focused Cognitive Behavioral Therapy","Evaluation of Blended CBT for PTSD in Regular Care: A New Format of Computer-Assisted Trauma-Focused Cognitive Behavioral Therapy: A Randomized Controlled Non-inferiority Trial","Inclusion Criteria:\n\n* PTSD according to Diagnostic and Statistical Manual of mental disorders 5 as primary problem\n* ≥ 18 years\n* Basic knowledge of speaking and writing Swedish\n* No other psychological treatment at the same time\n* No ongoing threats or violence\n* If antidepressant medication, stable dose 6 weeks before starting treatment\n* Have access to the internet and a computer\n* Willingness\u002Fability to participate after receiving information about what participation entails\n\nExclusion Criteria:\n\n* Other diagnosis or problem is assessed as primary to PTSD\n* Moderate to severe suicidal risk\n* PTSD from childhood trauma that the person cannot remember",{"count":76,"type":21},160,[24],"A Randomized Controlled Non-inferiority Trial testing if the new experimental Blended Trauma focused cognitive behavioral therapy (B-TF-CBT) for post traumatic stress disorder (PTSD), is non-inferior to gold standard control treatment Prolonged Exposure (PE).\n\nResearch question and hypothesis\n\nPrimary\n\n1. Is bTF-CT non-inferior to prolonged exposure (PE) when delivered in routine clinical care in terms of PTSD symptoms on the PCL-5 post-treatment?\n\n   Secondary:\n2. Is bTF-CT non-inferior to prolonged exposure (PE) when delivered in routine clinical care in terms of PTSD symptoms on the PCL-5 at 6 and 12 months follow up?\n3. Are there significant differences between bTF-CT and PE when delivered in routine clinical care in terms of depression, anxiety, insomnia, functionality, complex PTSD, other PTSD-measures and treatment satisfaction post-treatment and at 6 and 12 months follow up?\n\nThe study will be conducted at 3-6 outpatient clinics in Region Stockholm, Sweden.",[56,29],"2025-12-19",{"date":82,"type":34},"2025-12-26",{"date":84,"type":34},"2023-03-10",{"date":86,"type":21},"2027-10-10",{"name":88,"class":41},"Karolinska Institutet",{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":22,"phases":99,"briefSummary":100,"conditions":101,"keywords":106,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":42},"100583170","adapting-the-fear-of-recurrence-therapy-fort-for-parents-and-establishing-acceptability-and-feasibility-100583170","NCT06872840","Adapting The Fear Of Recurrence Therapy (FORT) for Parents and Establishing Acceptability and Feasibility","Addressing Fear of Cancer Recurrence in Parents of Pediatric Cancer Survivors: Adapting The Fear Of Recurrence Therapy (FORT) for Parents and Establishing Acceptability and Feasibility","Parent-FORT","Inclusion Criteria:\n\n* Parent (or primary caregiver) caring for a childhood cancer survivor (\\\u003C18 years of age) of any type of cancer type, who is at least 1 months from the completion of active treatment and has not had a recurrence of their cancer\n* A score of 13 or greater on the Fear of Cancer Recurrence Inventory-Short Form-Parent version (FCRI-SF-P; range 0-36), suggesting clinical levels of FCR\n* Access to a computer and internet connection\n* Living in Canada\n\nExclusion Criteria:\n\n* Being the parent of a pediatric cancer survivor who is now 18 years of age or older\n* Being the parent of a pediatric cancer survivor who has undergone hematopoietic cell transplantation and has active chronic or acute graft-versus-host disease which has not stabilized for at least 3 months\n* Non-English speakers\n* Currently participating in another therapist-led psychosocial therapy group\n* Parent with unmanaged\u002Fundermanaged mental health disorder judged to be clinically contraindicated and\u002For likely to affect the group work\n* To avoid violating the assumption of nonindependence of the data, only one parent\u002Fcaregiver per child can participate in the study.",{"count":98,"type":21},36,[24],"Clinical levels of fear of cancer recurrence (FCR) affect up to 59% of adult cancer survivors. Family caregivers experience equal or greater levels of FCR, which has been linked to lower quality of life and increased distress. FCR can be addressed in cancer survivors with brief interventions. However, none of these interventions have been tested with parents of childhood cancer survivors. This is an urgent gap: the survival rates of childhood cancer have increased more rapidly than for adult cancers, resulting in a growing population of childhood cancer survivors who, along with their families, need support.\n\nThe goals of this pilot study are to demonstrate 1) that a newly adapted intervention of FORT (Parent-FORT) is feasible (i.e., participant recruitment, attendance and participation) and acceptable (i.e., parent satisfaction of the intervention) for a larger study, and 2) the clinical implications of Parent-FORT on fear of cancer recurrence (FCR) and quality of life in parents of childhood cancer survivors.\n\nParents will be randomly assigned to participate in the Parent-FORT intervention immediately or a three-month waitlist control group. They will complete a questionnaire package before and after the intervention, as well as at a three month follow up. This study will help bridge an important gap in bringing evidence-based care to parents who have never been offered help before for their FCR.",[102,103,104,29,105],"Cancer","Parent","Fear of Cancer Recurrence","Childhood Cancer Survivors",[107,108,109],"Pilot study","Group Therapy","Virtual","2025-09-16",{"date":112,"type":34},"2025-09-22",{"date":114,"type":34},"2025-08-26",{"date":116,"type":21},"2027-05-26",{"name":118,"class":41},"University of Ottawa",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":130,"phases":4,"briefSummary":131,"conditions":132,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":42},"100596224","behavioral-therapy-and-glp-1-analogue-effects-on-binge-eating-weight-and-coping-in-obesity-100596224","NCT07042672","Behavioral Therapy and GLP-1 Analogue Effects on Binge Eating, Weight, and Coping in Obesity","Behavioral Therapy With and Without GLP-1 Analogue in Patients With Morbid Obesity and Binge Eating Disorder: A Clinical Prospective Observational Study on Body Weight, Binge Eating Behavior, and Harmful Coping Strategies","BETTER-GLP1","Inclusion criteria\n\n1. Severe obesity defined as BMI \\>40 kg\u002Fm2 or 35 kg\u002Fm2 with obesity-related comorbidities: coronary artery disease, heart failure, hypertension, atrial fibrillation, cerebral stroke, venous thromboembolism, obstructive sleep apnea, obesity hypoventilation syndrome, type 2 diabetes mellitus, non-alcoholic fatty liver disease, dyslipidemia, osteoarthritis and polecystic ovary syndrome\n2. Age between 18 to 65 years\n3. Diagnosis of BED according to DSM-5 criteria\n4. Willingness to participate and provide informed consent\n5. Able to understand and communicate in Norwegian\n\nExclusion criteria\n\n1. Pregnant or lactating women, as well as women planning pregnancy within one year.\n2. Current use medications with major effects on appetite regulation or weight (including, but not limited to systemic glucocorticoids and antipsychotic medication)\n3. Renal failure with estimated glomerular filtration rate less than 30 mL\u002Fmin\u002F1,73m2\n4. Liver failure with either ASAT and\u002For ALAT 5 times upper reference limit, or ALP and\u002For GT more than 3 times upper reference limit, or clinical signs of liver decompensation\n5. Active cancer\n6. Previous medullary thyroid cancer\n7. Previous pancreatitis\n8. Active substance abuse (but previous drug abuse accepted)\n9. Medical or psychological treatment within the specialized health care service for eating disorders within the last 6 months.\n10. Ongoing severe psychiatric disease that makes them unable to follow the lifestyle treatment program\n11. Any illness or prior treatment that in the opinion of the investigator would jeopardize the patient's participation in the study or impact integrity and\u002For quality of study data.\n12. Previous bariatric surgery\n13. Use of appetite suppressing drugs (e.g., GLP-1 analogues and\u002For naltrexone\u002Fbupropion) within the last 6 months\n14. Participation in another clinical study involving an investigational medicinal product within 1 month prior to study inclusion","65 Years",{"count":129,"type":21},80,"OBSERVATIONAL","This study is a clinical, longitudinal, non-randomized, prospective observational study that seeks to compare the treatment effects and safety of using GLP-1 analogues versus not using appetite suppressants during a lifestyle treatment program that includes individual consultations every fourth month and 10 weeks of CBT-E group therapy in patients with both obesity and BED.\n\nThe primary objective of this study is to evaluate the impact on BED symptomatology, while the secondary objectives include examining the potential adoption of alternative harmful coping mechanisms. Additionally, the study will assess psychological well-being and weight changes and their consequent influence on obesity-associated comorbid conditions.\n\nAdult patients with coexisting obesity and BED presenting at the Obesity clinic at Haukeland University Hospital, Bergen, Norway, will be included Patients will be divided into two groups: Group-GLP1 (n = 40), who will use GLP-1 analogues, and Group-NoMED (n = 40), who will not use appetite suppressants. Both groups will otherwise follow the routine standardized patient care pathway with follow-up controls every four months and participation in CBT group therapy sessions.\n\nChanges in symptoms of BED, alternative harmful coping strategies and mental health will be recorded at baseline and 12 months using patient-reported questionnaires, as well as anthropometric and biochemical data.",[133,134,135,136,137,29,138],"Binge Eating Disorder Associated With Obesity","Binge Eating Disorder","Eating Disorder Binge","Eating Disorders","GLP-1","Obesity &Amp; Overweight","2025-09-09",{"date":141,"type":34},"2025-09-15",{"date":143,"type":34},"2025-07-01",{"date":145,"type":21},"2028-12-31",{"name":147,"class":41},"Haukeland University Hospital",{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":155,"sex":16,"minAge":156,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":22,"phases":159,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":42},"100507670","sgm-evidenced-based-mental-healthcare-implementation-100507670","NCT05890404","SGM Evidenced-Based Mental Healthcare Implementation","Implementing Sustainable Evidence-based Mental Healthcare in Low-resource Community Settings Nationwide to Advance Mental Health Equity for Sexual and Gender Minority Individuals","Inclusion Criteria: Providers\n\nEligible providers will meet the following criteria:\n\n* 18 years of age or older\n* working as a psychologist, psychiatrist, social worker, mental health counselor, nurse practitioner, or peer support provider\n* affiliated with a US LGBTQ community center\n* providing mental health services to at least one sexual or gender minority (SGM) client\n\nExclusion Criteria: Providers\n\nProviders will be deemed ineligible due to:\n\n\\- possessing substantive experience with LGBTQ-affirmative CBT (e.g., having read most the LGBTQ-affirmative CBT treatment manual, attended LGBTQ-affirmative CBT training, or been supervised by someone who has previously attended the LGBTQ-affirmative CBT training)\n\nInclusion Criteria: Clients\n\nEligible clients will meet the following criteria:\n\n* of age to consent to mental health treatment in the state in which they live\n* receiving ongoing mental health services at one of the 15 LGBTQ centers selected for the client evaluation aim of the present study\n* self-identifying as LGBTQ\n\nExclusion Criteria: Clients\n\nThere are no exclusion criteria for clients",true,"15 Years",{"count":158,"type":21},1410,[24],"The purpose of the proposed study is to identify effective strategies for implementing lesbian, gay, bisexual, transgender, and queer (LGBTQ)- affirmative Cognitive-Behavioral Therapy (CBT) at LGBTQ community centers across the United States.",[29,162],"LGBTQ","2025-08-01",{"date":165,"type":34},"2025-08-05",{"date":167,"type":34},"2024-02-08",{"date":169,"type":21},"2028-06-30",{"name":171,"class":41},"Yale University",{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":179,"enrollmentInfo":180,"targetDuration":4,"studyType":130,"phases":4,"briefSummary":182,"conditions":183,"keywords":192,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":42},"100481446","cbt-and-the-neural-circuits-of-anxiety-100481446","NCT05549102","CBT and the Neural Circuits of Anxiety","The Impact of CBT on Shock-Potentiated Neural Circuity","Inclusion Criteria:\n\n* Enrolled in IAPT Step 3 (high intensity service)\n* Score of or above 8 on the GAD-7 (indicating moderate anxiety on a standard scale of anxiety; Spitzer et al., 2006)\n* Willing and able to provide written consent\n\nExclusion Criteria:\n\n* Score above 22 on the GAD-7\n* Past\u002Fpresent psychotic disorder, bipolar disorder\u002Fmania or alcohol\u002Fsubstance use disorder (outside a comorbid psychiatric episode)\n* History of medical illness that may impair cognitive function (e.g. serious head injury, endocrine disorder)\n* Current psychotropic pharmacological intervention (e.g. SSRIs) or use within 3 months\n* MRI contraindications such as pacemaker, aneurysm clip, cochlear implant, neurostimulator, IUD, shrapnel, metal fragments in eye, weight of above 250lbs or claustrophobia\n* Females who are pregnant, planning pregnancy, or breastfeeding","64 Years",{"count":181,"type":21},174,"This study will aim to test whether specific neural circuitry changes, proposed on the basis of a neurocognitive model of anxiety, are a mechanism of action for Cognitive Behavioural Therapy (CBT) interventions. This study aims to provide a theoretical model of the neurobiological mechanisms of CBT's therapeutic effect, where there currently is none, and potentially allow for more targeted\u002Fspecific approaches to anxiety disorders following the identification of key CBT mechanisms. The ultimate aim is to improve the efficacy of CBT, and more generally, psychological interventions for anxiety disorders.",[184,185,29,186,187,188,189,190,191],"Generalised Anxiety Disorder","Anxiety Disorders","Anxiety Depression","Anxiety Disorders and Symptoms","Anxiety Generalized","Anxiety","Anxiety Disorder Generalized","Anxiety Disorder; Mixed With Depression (Mild)",[193,194,195,196,29,197,198,199],"GAD","generalised anxiety disorder","anxiety disorders","cognitive behavioural therapy","psychological therapy","neural circuitry","emotional processing","2025-06-25",{"date":202,"type":34},"2025-06-29",{"date":204,"type":34},"2020-02-02",{"date":206,"type":21},"2025-12-01",{"name":208,"class":41},"UCLH\u002FUCL Joint Research Office",{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":16,"minAge":216,"maxAge":18,"enrollmentInfo":217,"targetDuration":4,"studyType":22,"phases":219,"briefSummary":220,"conditions":221,"keywords":223,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":238},"100591659","brief-cognitive-behaviour-therapy-cbt-for-adolescent-ocd-in-routine-clinical-practice-100591659","NCT06983301","Brief Cognitive Behaviour Therapy (CBT) for Adolescent OCD in Routine Clinical Practice","A Feasibility Study of Brief Cognitive Behaviour Therapy for Adolescent OCD in Routine Clinical Practice","Inclusion Criteria:\n\nYoung people:\n\n* Willing and able to give informed assent (if aged 11-15 years, and parent\u002Fcarer consent is provided) or consent (if aged 16-18 years) for participation in the study.\n* Aged 11 to 18 years at the time of recruitment.\n* Diagnosed with OCD using the Anxiety Disorders Interview Schedule (ADIS) and OCD has been identified as the primary problem.\n* If on pharmacotherapy for OCD, then stable dose for at least 6 weeks prior to trial entry.\n* Able to speak and read English at a sufficient level to be able to read and understand the workbooks and materials and complete exercises in the workbooks.\n* Willing to engage in the treatment.\n* In the Investigator's opinion, is able and willing to comply with all trial requirements.\n* Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the trial.\n\nParents\u002Fcarers:\n\n* Able and willing to provide written informed consent for their child's participation in the study.\n* Able to read the parent\u002Fcarer workbook and materials.\n* Willing and able to participate.\n\nClinicians:\n\n* Working within a participating NHS or NHS-commissioned service.\n* Have a professional qualification in psychological therapy that includes training in CBT at or above post-graduate certificate level.\n* Willing to participate.\n* Clinical capacity and managerial approval to participate\n\nExclusion Criteria:\n\nYoung people:\n\n* The clinical assessment indicates that risk\u002Fsafeguarding cannot be safely managed within the service.\n* Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial.\n* Evidence of learning difficulties identified by schools or evident at interview that would inhibit participation in cognitive components of therapy.\n* Currently receiving a psychological intervention for OCD.\n\nParents\u002Fcarers:\n\n* No exclusion criteria.\n\nClinicians:\n\n* No exclusion criteria","11 Years",{"count":218,"type":21},25,[24],"Obsessive-Compulsive Disorder (OCD) is a common and often disabling condition in young people, characterised by distressing, intrusive thoughts, images or urges, and repetitive behaviours intended to reduce discomfort or prevent harm. Around 1% of adolescents in the UK experience OCD, with many cases beginning in childhood or adolescence. Cognitive Behavioural Therapy (CBT) is the recommended treatment for OCD in young people, but access to treatment is limited due to high demand, long waiting lists, and lack of trained clinicians.\n\nA brief form of CBT for OCD, supported by workbooks, has previously shown promising results in research settings. However, it remains unclear whether this approach is feasible, acceptable, and effective when delivered within routine NHS child and adolescent mental health services (CAMHS), especially for young people with co-occurring autism.\n\nThis single-arm feasibility trial aims to explore whether brief CBT can be delivered effectively in routine NHS and NHS-commissioned services to young people aged 11-18 years with OCD as their main presenting problem. The trial will also assess whether the intervention is acceptable to young people, their parents\u002Fcarers, and clinicians, and whether outcomes are comparable to existing evidence.\n\nIntervention Overview: The brief CBT intervention consists of five core sessions, with the option of two additional booster sessions, delivered over 24 weeks. Sessions are delivered face-to-face by trained clinicians and last between 60 to 90 minutes. The intervention is supported by a series of co-designed workbooks to be completed by the young person between sessions. Parents\u002Fcarers are also provided with a workbook and encouraged to support the young person's progress where appropriate. Sessions may take place in the clinic or in other agreed settings, such as at home or school. The frequency of sessions decreases over time, with the first four sessions delivered weekly and later sessions spaced further apart.\n\nThe intervention includes psychoeducation, developing a cognitive-behavioural understanding of OCD, goal setting, and techniques to support motivation and engagement. A key focus is helping young people develop cognitive flexibility by testing and challenging unhelpful beliefs that drive OCD behaviours, supported by behavioural experiments. Parents\u002Fcarers and other adults in the young person's life may also be involved to help generalise learning and promote progress.\n\nTrial Aims: The trial has two primary aims:\n\nTo establish whether brief CBT for OCD can be delivered with fidelity and acceptability by clinicians in NHS services, and is acceptable to young people and their families.\n\nTo explore whether the intervention is associated with significant improvements in OCD symptoms for young people, including those with autism or high levels of autistic traits.\n\nTrial Design: The study is a single-arm feasibility trial. Between 20-30 young people aged 11-18 years will be recruited alongside their parents\u002Fcarers. Approximately 8-10 clinicians will be trained to deliver the intervention. OCD symptoms, treatment processes, and acceptability will be assessed at baseline, post-treatment (12 weeks), and at 3-month follow-up (24 weeks). Additional measures will be collected before each therapy session.\n\nQualitative interviews will be conducted with young people, parents\u002Fcarers, and clinicians to understand their experiences of the intervention. Acceptability will also be measured using standardised questionnaires completed during and after treatment.\n\nOutcomes: The primary outcomes are feasibility and acceptability of the intervention, assessed through session attendance, participant engagement, clinician adherence, and feedback from young people, parents\u002Fcarers, and clinicians.\n\nSecondary outcomes include changes in OCD symptoms, responsibility beliefs, family accommodation, and overall functioning, as well as measures of anxiety and depression. Data will be analysed to assess changes from baseline to post-treatment and follow-up, including for young people with and without autistic traits. Treatment adherence and clinician competence will also be evaluated.",[222,29],"Obsessive Compulsive Disorder (OCD)",[224,225,29,226,227,228],"OCD","Adolescent mental health","Cognitive Behavioural Therapy","Brief psychological therapy","Obsessive Compulsive Disorder","2025-05-13",{"date":231,"type":34},"2025-05-21",{"date":233,"type":34},"2025-05-02",{"date":235,"type":21},"2026-03-31",{"name":237,"class":41},"University of Oxford",3,{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":22,"phases":247,"briefSummary":248,"conditions":249,"keywords":252,"overallStatus":259,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":42},"100511678","effects-of-cbt-based-intervention-among-patients-with-liver-cancer-100511678","NCT05942560","Effects of CBT-Based Intervention Among Patients With Liver Cancer","Effects of Cognitive Behavioral Therapy-Based Intervention on Depression, Anxiety, Quality of Life, Immune Indicators, and Survival Among Patients With Liver Cancer","Inclusion Criteria:\n\n1. Adults (aged ≥18);\n2. Diagnosed with liver cancer based on pathological findings or imaging findings in the medical record;\n3. The severity level of depression and anxiety: Depression \\> 7 using HAD-D, or Anxiety \\> 7 using HAD-A (Hospital Anxiety and Depression Scale, HADS; HAD-D, Hospital Depression Scale; HAD-A, Hospital Anxiety Scale).\n\nExclusion Criteria:\n\n1. Patients who are taking part in another psychological intervention clinical trial or consented to receive another psychotherapy, suffered from aphasia and other communication difficulties will be excluded from the study\n2. Patients with active immunological diseases, such as autoimmune diseases, and inflammatory diseases.\n3. Patients accepting hormone therapy or taking long-term antibiotic drugs.\n4. Patients who lack the basic ability of understanding and expression and are incompetent in giving consent.",{"count":76,"type":21},[24],"This study investigates the effects of a CBT- based intervention on depression, anxiety, immune function, quality of life, and overall survival. It also explores if the effects of the intervention on immune function and quality of life are mediated through the improvements in depression and anxiety among patients with liver cancer.",[250,189,251,29],"Depression","Liver Cancer",[196,253,254,255,256,257,258],"depression","anxiety","immune","quality of life","survival","liver cancer","NOT_YET_RECRUITING","2023-11-21",{"date":262,"type":34},"2023-11-22",{"date":264,"type":21},"2023-12-30",{"date":266,"type":21},"2029-06-30",{"name":268,"class":41},"The Nethersole School of Nursing"]